经导管肝动脉化疗栓塞联合康莱特注射液对原发性肝癌患者瘤体体积及生活质量的影响

目的探讨经导管肝动脉化疗栓塞联合康莱特注射液对原发性肝癌瘤体体积及生活质量的影响。方法选取2016年10月—2018年9月期间收治的100例原发性肝癌患者为研究对象,根据治疗方法不同,随机分为对照组和治疗组,每组50例,对照组给予经导管肝动脉化疗栓塞,治疗组实施导管肝动脉化疗栓塞联合康莱特注射液治疗,观察并比较两组患者的临床疗效、瘤体体积变化、生存质量以及不良反应等指标。结果治疗后治疗组的临床总有效率88.0%(44/50)高于对照组68.0%(34/50),差异有统计学意义(P<0.05)。治疗后两组患者瘤体体积均小于治疗前,差异有统计学意义(P<0.05),且治疗组的瘤体体积小于对照组,差异有统计学意义(P<0.05)。治疗后两组患者生活质量均高于治疗前,差异有统计学意义(P<0.05),且治疗组患者的生活质量高于对照组,差异有统计学意义(P<0.05)。治疗后治疗组的不良反应总发生率4.0%(2/50)低于对照组12.0%(6/50),差异有统计学意义(P<0.05)。结论针对原发性肝癌患者给予经导管肝动脉化疗栓塞联合康莱特注射液治疗,能有效提高患者的临床疗效,减小肝癌瘤体体积,提高患者的生活质量,降低不良反应发生率,值得临床上推广使用。

Effect of transcatheter arterial chemoembolization combined with Kanglaite Injection on tumor volume and quality of life in patients with primary liver cancer

Objective To investigate the effect of transcatheter arterial chemoembolization(TACE)combined with Kanglaite Injection on tumor volume and quality of life in patients with primary liver cancer(PLC).Methods A total of 100 PLC patients admitted to our hospital from October,2016 to September,2018 were randomized into the control group and the treatment group,with 50 cases in each group.The control group was given TACE,while the treatment group was given Kanglaite Injection combined with TACE.The linical efficacy,change of tumor volume,quality of life and adverse events were observed.Results After treatment,the total effective rate in the treatment group was 88.0%,which was higher than that(68.0%)of the control group,with statistical significance(P<0.05).After treatment,tumor volume in both group decreased compared with that before treatment with statistical significance(P<0.05),and the treatment group had smaller volume than the control group,with statistical significance(P<0.05).After treatment,quality of life in both groups was improved compared with that before treatment,with statistical significance(P<0.05),and the treatment group had higher quality of life score than the control group,with statistical significance(P<0.05).The incidence of adverse events was 4.0%in the treatment group,which was significantly lower than that(12.0%)in the control group,with statistical significance(P<0.05).Conclusion For primary liver cancer,Kanglaite Injection combined with TACE can effectively improve the clinical efficacy,reduce the volume of tumor,improve the quality of life and reduce the incidence of adverse events,which is worthy of clinical application.